150 related articles for article (PubMed ID: 32596342)
21. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
[No Abstract] [Full Text] [Related]
22. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma.
Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH
J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma.
Ma X; Ding Y; Zeng L
BMC Cancer; 2021 Apr; 21(1):418. PubMed ID: 33858382
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of sexual dimorphism‑linked gene expression profile in hepatocellular carcinoma.
Wu Y; Yao N; Feng Y; Tian Z; Yang Y; Zhao Y
Oncol Rep; 2019 Sep; 42(3):937-952. PubMed ID: 31322260
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
26. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
[No Abstract] [Full Text] [Related]
27. The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma.
Deng M; Sun S; Zhao R; Guan R; Zhang Z; Li S; Wei W; Guo R
Mol Med; 2022 Feb; 28(1):16. PubMed ID: 35123387
[TBL] [Abstract][Full Text] [Related]
28. Identification of Key Biological Processes, Pathways, Networks, and Genes with Potential Prognostic Values in Hepatocellular Carcinoma Using a Bioinformatics Approach.
Lu H; Zhu Q
Cancer Biother Radiopharm; 2021 Dec; 36(10):837-849. PubMed ID: 32598174
[No Abstract] [Full Text] [Related]
29. Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study.
Wang Y; Huang Q; Deng T; Li BH; Ren XQ
Med Sci Monit; 2019 May; 25():3894-3901. PubMed ID: 31128068
[TBL] [Abstract][Full Text] [Related]
30. Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis.
Liu J; Han F; Ding J; Liang X; Liu J; Huang D; Zhang C
Biomed Res Int; 2021; 2021():8849415. PubMed ID: 34337056
[TBL] [Abstract][Full Text] [Related]
31. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
32. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma.
Shi Q; Meng Z; Tian XX; Wang YF; Wang WH
Future Oncol; 2021 Jun; 17(17):2193-2208. PubMed ID: 33620260
[TBL] [Abstract][Full Text] [Related]
33. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.
Han ZB; Zhong L; Teng MJ; Fan JW; Tang HM; Wu JY; Chen HY; Wang ZW; Qiu GQ; Peng ZH
Mol Oncol; 2012 Aug; 6(4):445-57. PubMed ID: 22552153
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma.
Long J; Chen P; Lin J; Bai Y; Yang X; Bian J; Lin Y; Wang D; Yang X; Zheng Y; Sang X; Zhao H
Theranostics; 2019; 9(24):7251-7267. PubMed ID: 31695766
[TBL] [Abstract][Full Text] [Related]
35. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
36. Identification of immune-infiltrating cell-related biomarkers in hepatocellular carcinoma based on gene co-expression network analysis.
Hou Y; Zhang G
Diagn Pathol; 2021 Jul; 16(1):57. PubMed ID: 34218795
[TBL] [Abstract][Full Text] [Related]
37. Oncogene PLCE1 may be a diagnostic biomarker and prognostic biomarker by influencing cell cycle, proliferation, migration, and invasion ability in hepatocellular carcinoma cell lines.
Wang XK; Liao XW; Yang CK; Liu ZQ; Han QF; Zhou X; Zhang LB; Deng T; Gong YZ; Huang JL; Huang R; Han CY; Yu TD; Su H; Ye XP; Peng T; Zhu GZ
J Cell Physiol; 2020 Oct; 235(10):7003-7017. PubMed ID: 32037547
[TBL] [Abstract][Full Text] [Related]
38. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma.
Zhu S; Huang X; Zhang K; Tan W; Lin Z; He Q; Chen Y; Shang C
Cancer Med; 2019 Dec; 8(18):7679-7692. PubMed ID: 31674731
[TBL] [Abstract][Full Text] [Related]
39. Long non‑coding RNA‑based risk scoring system predicts prognosis of alcohol‑related hepatocellular carcinoma.
Luo Y; Ye J; Wei J; Zhang J; Li Y
Mol Med Rep; 2020 Aug; 22(2):997-1007. PubMed ID: 32468063
[TBL] [Abstract][Full Text] [Related]
40. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
